News

Patients likely to have prodromal, or early, Parkinson’s disease tend to have a higher prevalence of pain, according to a new study. The findings indicate that pain may be a relevant disease marker before the appearance of motor disturbances. The study, “Pain: A marker of prodromal Parkinsons disease?”…

Nilotinib can modulate dopamine levels and metabolism, as well as prevent the formation of toxic alpha-synuclein aggregates, according to recent data from a Phase 2 clinical trial. These findings suggest that Novartis’ investigational therapy has the potential to promote long-term benefits in patients with Parkinson’s disease. The study, “…